Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: The MARI study

Clinical and Experimental Rheumatology

Volumn 33, Issue 6, 2015, Pages 895-899

  Idolazzi, Luca ^a   Adami, Silvano ^a   Capozza, Riccardo ^b   Bianchi, Gerolamo ^c   Cozzolongo, Annacarla ^d   Epis, Oscar ^e   Fusaro, Enrico ^f   Lapadula, Giovanni ^g   Migliore, Alberto ^h   Pellerito, Raffaele ⁱ   Pucino, Angelo ^j   Sinigaglia, Luigi ^k   Visalli, Elisa ^l   Rossini, Maurizio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b CTO Hospital ASL Roma C   (Italy)

^c Ospedale La Colletta   (Italy)

^d San Paolo Hospital   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f Azienda Ospedaliero Universitaria S Giovanni Battista   (Italy)

^g Ospedale Consorziale Policlinico   (Italy)

^h FATEBENEFRATELLI HOSPITAL   (Italy)

ⁱ MAURIZIANO HOSPITAL   (Italy)

^j ASL Napoli 1 Centro Distretti 24 27 31   (Italy)

^k ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^l UNIVERSITY OF MESSINA   (Italy)

more..

Author keywords

Methotrexate; Oral; Parenteral; Rheumatoid arthritis; Therapy

Indexed keywords

ANTIRHEUMATIC AGENT; GLUCOCORTICOID; METHOTREXATE; RHEUMATOID FACTOR;

AGED; ARTHRITIS, RHEUMATOID; BLOOD; DOSE RESPONSE; DRUG COMBINATION; FEMALE; HUMAN; ITALY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ACUITY; PROCEDURES; REMISSION; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; ITALY; MALE; METHOTREXATE; MIDDLE AGED; PATIENT ACUITY; REMISSION INDUCTION; RHEUMATOID FACTOR; TREATMENT OUTCOME;

EID: 84957973330     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ALETAHA D, SMOLEN JS: The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002; 41: 1367-74.
2. MAETZEL A, WONG A, STRAND V, TUGWELL P, WELLS G, BOMBARDIER C: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving diseasemodifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39: 975-81.
3. VISSER K, VAN DER HEIJDE D: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68: 1094-9.
4. VISSER K, KATCHAMART W, LOZA E et al: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-93.
5. GOODMAN SM, CRONSTEIN BN, BYKERK VP: Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol 2015; 33: 272-8.
6. CURTIS JR, ZHANG J, XIE F et al: Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken) 2014; 66: 1604-11.
7. ARNETT FC, EDWORTHY SM, BLOCH DA et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
8. SCHIFF MH, JAFFE JS, FREUNDLICH B: Headto-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014; 73: 1549-51.
9. BAKKER MF, JACOBS JWG, WELSING PMJ et al: Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010; 69: 1849-52.
10. BRAUN J, KÄSTNER P, FLAXENBERG P et al: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73-81.
11. YAZICI H: Methotrexate and not much harm to the lungs. Clin Exp Rheumatol 2014; 32 (6 Suppl. 87): S10.
12. JUNDT JW, BROWNE BA, FIOCCO GP, STEELE AD, MOCK D: A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-9.
13. HOEKSTRA M, HAAGSMA C, NEEF C, PROOST J, KNUIF A, VAN DE LAAR M: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-8.
14. PICHLMEIER U, HEUER K-U: Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol 2014; 32: 563-71.
15. ROZIN A, SCHAPIRA D, BALBIR-GURMAN A et al: Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002; 61: 756-7.
16. WEGRZYN J, ADELEINE P, MIOSSEC P: Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1232-4.
17. DE LEONARDIS F, ALIVERNINI S, BONACCI E et al: [Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the «3E initiative»]. Reumatismo 2010; 62: 34-45.
18. TODOERTI M, MAGLIONE W, BERNERO E et al: Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis. 2013; 65: 207-18.
19. KRAUSE D, GABRIEL B, HERBORN G, BRAUN J, RAU R: The positive influence of methotrexate on the mortality of patients with rheumatoid arthritis is partly independent of its effect on disease activity: results of a re-evaluation 18 years after baseline. Clin Exp Rheumatol 2014; 32: 395-400.